{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+hydrochloride+%28Glucophage%C2%AE%29&page=4", "query": { "intervention": "Metformin hydrochloride (Glucophage®)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 81, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+hydrochloride+%28Glucophage%C2%AE%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+hydrochloride+%28Glucophage%C2%AE%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T04:27:04.989Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00975286", "title": "24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Thiazolidinedione (TZD)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2009-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 23, "location_summary": "Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mountain Home", "state": "Arkansas" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975286" }, { "nct_id": "NCT02269098", "title": "The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 2", "Medication Adherence", "HYPERGLYCEMIA" ], "interventions": [ { "name": "Diabetes medication management", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Medstar Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2012-02", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269098" }, { "nct_id": "NCT00046462", "title": "Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Lantus (insulin glargine [rDNA origin] injection)", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Glyburide", "type": "DRUG" }, { "name": "Thiazolidinedione", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 240, "start_date": "2001-11", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2011-01-11", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046462" }, { "nct_id": "NCT00865436", "title": "A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg", "type": "DRUG" }, { "name": "CLUCOVANCE® 5 mg/500 mg Tablets, single dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2004-04", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2010-08-17", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00865436" }, { "nct_id": "NCT02009488", "title": "Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin, 100 mg", "type": "DRUG" }, { "name": "Canagliflozin, 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "25 Years to 70 Years" }, "enrollment_count": 59, "start_date": "2014-09-08", "completion_date": "2017-01-03", "has_results": false, "last_update_posted_date": "2018-01-04", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 2, "location_summary": "San Diego, La Jolla, California • Gainesville, Florida", "locations": [ { "city": "San Diego, La Jolla", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009488" }, { "nct_id": "NCT00727857", "title": "Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Pioglitazone and metformin", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2007-06", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2011-07-29", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00727857" }, { "nct_id": "NCT00778466", "title": "Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fed Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "metformin hydrochloride 1000 mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ranbaxy Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 32, "start_date": "2006-02", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2008-10-23", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT00778466" }, { "nct_id": "NCT00986401", "title": "Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Trospium Chloride (Sanctura XR®)", "type": "DRUG" }, { "name": "Metformin hydrochloride (Glucophage®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 44, "start_date": "2009-10", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2011-12-19", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00986401" }, { "nct_id": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Breast Tumors", "Angiosarcoma", "TNBC - Triple-Negative Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Tumor", "Hormone Receptor Negative Tumor", "Early-stage Breast Cancer", "Locally Advanced Breast Cancer" ], "interventions": [ { "name": "Standard Therapy", "type": "DRUG" }, { "name": "AMG 386 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 479 (Ganitumab) plus Metformin", "type": "DRUG" }, { "name": "MK-2206 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 386 and Trastuzumab", "type": "DRUG" }, { "name": "T-DM1 and Pertuzumab", "type": "DRUG" }, { "name": "Pertuzumab and Trastuzumab", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" }, { "name": "ABT-888", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab - 4 cycle", "type": "DRUG" }, { "name": "Talazoparib plus Irinotecan", "type": "DRUG" }, { "name": "Patritumab and Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab - 8 cycle", "type": "DRUG" }, { "name": "SGN-LIV1A", "type": "DRUG" }, { "name": "Durvalumab plus Olaparib", "type": "DRUG" }, { "name": "SD-101 + Pembrolizumab", "type": "DRUG" }, { "name": "Tucatinib plus trastuzumab and pertuzumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab plus REGN3767", "type": "DRUG" }, { "name": "Trilaciclib with or without trastuzumab + pertuzumab", "type": "DRUG" }, { "name": "SYD985 ([vic-]trastuzumab duocarmazine)", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab", "type": "DRUG" }, { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Amcenestrant + Abemaciclib", "type": "DRUG" }, { "name": "Amcenestrant + Letrozole", "type": "DRUG" }, { "name": "ARX788", "type": "DRUG" }, { "name": "ARX788 + Cemiplimab", "type": "DRUG" }, { "name": "VV1 + Cemiplimab", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan + Durvalumab", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Lasofoxifene", "type": "DRUG" }, { "name": "Z-endoxifen", "type": "DRUG" }, { "name": "ARV-471", "type": "DRUG" }, { "name": "ARV-471 + Letrozole", "type": "DRUG" }, { "name": "ARV-471 + Abemaciclib", "type": "DRUG" }, { "name": "Endoxifen + Abemaciclib", "type": "DRUG" }, { "name": "Rilvegostomig + TDXd", "type": "DRUG" }, { "name": "Dan222 + Niraparib", "type": "DRUG" }, { "name": "Sarilumab + Cemiplimab + Paclitaxel", "type": "DRUG" }, { "name": "GSK 5733584", "type": "DRUG" }, { "name": "GSK 5733584 + Dostarlimab", "type": "DRUG" }, { "name": "Ivonescimab (20mg/kg Q3W)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2010-03-01", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042379" }, { "nct_id": "NCT02065752", "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Canagliflozin, 100 mg", "type": "DRUG" }, { "name": "Metformin XR, 500 mg", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 1, 50 mg/500 mg", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 2, 50 mg/500 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 2, "start_date": "2014-02", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-06-17", "last_synced_at": "2026-10-12T04:27:04.989Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065752" } ] }